REMD 477

Drug Profile

REMD 477

Alternative Names: AMG477; REMD477

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator Amgen
  • Developer REMD Biotherapeutics
  • Class Antihyperglycaemics
  • Mechanism of Action G protein-coupled receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus
  • Phase I Type 1 diabetes mellitus

Most Recent Events

  • 01 Jan 2017 REMD Biotherapeutics completes a phase Ib trial in Type-1 diabetes mellitus in USA (NCT02715193)
  • 01 Mar 2016 Phase-I clinical trials in Type-1 diabetes mellitus in USA (SC) (NCT02715193)
  • 15 Dec 2015 The US FDA approves a phase Ib trial in Type-1 diabetes mellitus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top